Molecular-targeted therapy of venous thromboembolism

静脉血栓栓塞的分子靶向治疗

• 批准号: 22791206
• 负责人: FURUKOUJI Eiji
• 金额: $ 2.41万
• 依托单位: University of Miyazaki
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2010
• 资助国家: 日本
• 起止时间: 2010 至 2011
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22791206/
• 关键词: 深部静脈血栓症; 遺伝子導入; 静脈; Clec-2; CLEC-2

Platelet activation receptor CLEC-2 binds to podoplanin, thereby leading to platelet activation and thrombus formation. The present study examines whether local gene transfer suppress platelet aggregation and thrombus formation after adenovirus-mediated gene transfer to venous wall competitively. As a result, although further studies are needed, the possibility of persistent expression of target protein and antithrombotic effect were suggested in a rat model of venous thrombosis.

血小板活化受体CLEC-2与泊多拉宁结合，从而导致血小板活化和血栓形成。本研究旨在探讨局部基因转移对腺病毒介导的静脉壁基因转移后的血小板聚集和血栓形成是否具有竞争性抑制作用。因此，尽管还需要进一步的研究，但在静脉血栓形成的大鼠模型中，靶蛋白持续表达和抗血栓作用的可能性被提出。